Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.34 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.34 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL904646 | 0.91 | GABRR1 (0.50) | GABRR1CYP1A2ENPEPLTA4HALDH1A1 | |
| SCHEMBL2191 | 0.84 | — | — | |
| SCHEMBL21114361 | 0.84 | GABRR1 (0.65) | GABRR1CYP1A2ENPEPLTA4HSLC7A5 | |
| SCHEMBL565484 | 0.84 | — | — | |
| SCHEMBL456709 | 0.84 | — | — | |
| SCHEMBL17113671 | 0.84 | GABRR1 (0.43) | GABRR1CYP1A2ENPEPLTA4HALDH1A1 | |
| Hydrochloric Acid SCHEMBL27599300 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL2582220 | 0.82 | — | — | |
| Water SCHEMBL1565541 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL27603637 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023076257-A1 | METHODS FOR DIAGNOSING LEPTOMININGEAL METASTASIS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| CN-112074289-A | Thioether cyclic peptide amylin receptor modulators | 詹森药业有限公司 | 2020-12-11 | — | — | CN | disclosed |
| EP-3658169-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Yeda Research and Development Co. Ltd (IL) | 2020-06-03 | — | — | EP | disclosed |
| WO-2019021284-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2019-01-31 | — | — | WO | disclosed |
| EP-3046929-A1 | ERK-DERIVED PEPTIDES AND USES THEREOF | Yeda Research and Development Co., Ltd. (IL) | 2016-07-27 | — | — | EP | disclosed |
| WO-2015040609-A1 | ERK-DERIVED PEPTIDES AND USES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2015-03-26 | — | — | WO | disclosed |
| EP-2597464-B1 | Metabolomic profiling of prostate cancer | UNIV MICHIGAN (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-2597464-A2 | Metabolomic profiling of prostate cancer | The Regents of the University of Michigan (US) | 2013-05-29 | — | — | EP | disclosed |
| WO-2011080102-A2 | GLP-1 ANALOGUES AND DERIVATIVES | NOVO NORDISK A/S (DK) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011080103-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2011-07-07 | — | — | WO | disclosed |
| US-20110166321-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2011-07-07 | — | — | US | disclosed |
| WO-2011073328-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS WITH A MODIFIED N-TERMINUS | NOVO NORDISK A/S (DK) | 2011-06-23 | — | — | WO | disclosed |
| EP-2179292-A1 | METABOLOMIC PROFILING OF PROSTATE CANCER | The Regents of the University of Michigan (US) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009026152-A1 | METABOLOMIC PROFILING OF PROSTATE CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166321-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | GLP1R, IAPP, GCG | GABRR1 2742/4885CYP1A2 3626/4885ENPEP 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.